Drug profile · INN
clindamycin palmitate hydrochloride
CLINDAMYCIN PALMITATE HYDROCHLORIDE
clindamycin palmitate hydrochloride (CLINDAMYCIN PALMITATE HYDROCHLORIDE) is a bacterial 70s ribosome inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — clindamycin palmitate hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
clindamycin palmitate hydrochloride (CLINDAMYCIN PALMITATE HYDROCHLORIDE) is a bacterial 70s ribosome inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is clindamycin palmitate hydrochloride?
clindamycin palmitate hydrochloride (CLINDAMYCIN PALMITATE HYDROCHLORIDE) is a bacterial 70s ribosome inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for clindamycin palmitate hydrochloride?
CLINDAMYCIN PALMITATE HYDROCHLORIDE is a marketed brand name for clindamycin palmitate hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of clindamycin palmitate hydrochloride?
clindamycin palmitate hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.